He said the enrollment in Latin america was going well, last CC. They are looking to incorporate more arms into the mix, like those strains that are colistin resistant. This might help with specific labeling, small populations for specific pathogens. The EU is farther along regarding using small groups for specific life threatening cases from what he was saying. Maybe the new legislation in US will eventually help, ie ADAPT. May help all antibiotics companies. There was a general adcom panel on this, yesterday.
Nothing is guaranteed, I agree we will see $15-18 even before approval. FDA workers are forbid from buying stocks in drug companies from what I have heard, unless they want jail time, so I do not and will not work for them, too much money to rake in being a stockholder.
It's Ok, they will be a source of fuel for this rocket. KABOOM, I have seen many turned into vapor trails on other stocks.
I took it as they are looking to include more subgroups, from Nov 11, (look at that slide deck and listen to presentation, mentioned FDA panel yesterday, and they expect to update strategy in Jan.). I am thinking looking to develop the subgroups would help overall (ie- colistin resistant groups). I have some AKAO, between them and CEMP little else pure play on horizon in antibiotics. I have some TTPH also, it is in nosebleed seats, still holding it.
Thou shalt have no false gods, LOL, ISIS? Best to you, I too have a ton of CEMP. Some TTPH still, not all of my original, I have a good amount left, and some new AKAO shares, I don't know what else to target, now, open to some new ones to do DD on.
CEMP and TTPH used to trade about the same price range before TTPH reported data. Does this indicate CEMP should head to about $32 if data is looking good? I am thinking it should.
LOBSTER, for TSRX CVR we need to follow CBST, I don't think I can predict until more sales numbers come out, how much it might pay. Best as always.
It may be on page 40 (page 53 if scrolling the PDF and at bottom of page) of the agreement. I just looked in my old email from broker and found the merger offer. I was hoping CVR could be paid early if CBST is bought out, but this looks like they may be able to amended if a "person" succeeds CBST. I am not 100% sure, though as the wording is strange. If this deal with MRK happens I would be calling CBST IR to clarify.
Researcher, when were the 2 protocols sent to FDA? Morris said we could hear if the protocols are viable for bench testing and human factors/IFU in 30 days.
I smell shortie bacon roasting on the fire-pit. Shortie drippings are pure flammable rocket fuel. We should be way higher, soon - stay buckled in while we are soaring higher. Too bad Beav isn't here after all we went through in TSRX, getting that victory.
I heard that much. LOL, she don't like Pen Head. I don't think she smokes 2 packs, I think Pen Head is doing too many beer bongs and other type bongs with stillbongo. LOLZ
Freddy, do you like a cheap KnockOut? AKAO has a drug about to go in Phase 3 for CRE. They have Barda money (stacks of it), Gain benefits, and ADAPT advantages possible. It is way cheaper than IPO and has BIG inst. ownership. Look at slides on website, still a ways to go, but with antibioticaville real estate being snatched up, it may be a bustling Burb at some point. The board is dead, and I like to be early so I don't wind up expending too much ammo and energy to get the prey item.
I know, I saw you playing bridge with those gals and then Yatzee, boy they are clamoring around. Don't forget to send them a Christmas present.